MYCN and Burkitt lymphoma: This group went on to show that multiple N-MYC amplified neoplasms including lung cancer, medulloblastoma, neuroblastoma, and Burkitt’s lymphoma were susceptible to NAMPT inhibition with GMX1778 at nanomolar concentrations.